MorphoSys (ETR:MOR) has been given a €57.00 ($70.37) target price by analysts at Royal Bank of Canada in a research note issued to investors on Wednesday. The brokerage presently has a “sell” rating on the stock. Royal Bank of Canada’s price target suggests a potential downside of 22.29% from the stock’s current price.
A number of other brokerages also recently commented on MOR. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the company a “buy” rating in a research report on Thursday, December 7th. Commerzbank set a €76.00 ($93.83) price objective on MorphoSys and gave the company a “buy” rating in a report on Tuesday, November 7th. JPMorgan Chase & Co. reissued a “buy” rating and set a price objective on shares of MorphoSys in a report on Thursday, November 2nd. Deutsche Bank set a €90.00 ($111.11) price objective on MorphoSys and gave the company a “buy” rating in a report on Monday, October 30th. Finally, Oddo Bhf set a €81.00 ($100.00) price objective on MorphoSys and gave the company a “buy” rating in a report on Thursday, October 26th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. MorphoSys has an average rating of “Hold” and an average price target of €79.10 ($97.65).
Shares of MorphoSys (MOR) traded up €0.55 ($0.68) on Wednesday, hitting €73.35 ($90.56). The company had a trading volume of 103,888 shares, compared to its average volume of 141,076. The stock has a market capitalization of $2,140.00 and a P/E ratio of -24.86. MorphoSys has a one year low of €48.25 ($59.57) and a one year high of €87.35 ($107.84).
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.